Regencell Bioscience Holdings Limited (RGC) Cash Flow Statement

Because operating cash flow and net income move in the same direction with a ratio near 0.80, the reported losses appear to reflect real cash outflows rather than accounting noise. Several quarters lack disclosed operating cash flow entirely, so the conversion relationship cannot be tested consistently across the full ten-quarter window. Investors should monitor whether the cash-backed nature of losses persists as overhead continues to rise.

Free cash flow has been negative in every quarter where it is reported, and the absence of a revenue denominator means margin-based assessment is not possible from the supplied data. The directional signal is one of sustained cash consumption rather than any improving trend. This warrants further investigation into the funding runway implied by the most recent quarterly burn.

Low capex relative to operating outflows indicates that cash consumption is driven by operating expenses rather than infrastructure investment. Depreciation and amortization of roughly $364K in 2026Q4 exceeds the near-zero capex recorded in that period, implying the asset base is being run down rather than replaced. This pattern suggests limited near-term reinvestment in productive capacity.

The absence of dividends is consistent with a company in an early commercial or development stage, but the $1.8M of repurchases in 2026Q4 alongside a $5.1M operating outflow is an unusual allocation that warrants scrutiny. Investors should monitor whether buybacks continue while the company is consuming cash in operations, as this would reduce financial flexibility. The rationale for these repurchases is not disclosed in the supplied data.